-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR ARCUTIS’ ZORYVE® (ROFLUMILAST) CREAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AGES 2 TO 5

Reuters·11/17/2025 13:00:04

Please log in to view news